Oral drug therapy for erectile dysfunction

Urol Clin North Am. 2001 May;28(2):321-34. doi: 10.1016/s0094-0143(05)70141-5.

Abstract

Oral drugs are a well-established, first-line therapy for erectile dysfunction. As a result of the success of sildenafil, a plethora of new drugs for erectile dysfunction are on the horizon. Apomorphine and IC351 are in late phase III development. Vardenafil (Bayer, New Haven, CT), a PDE5 inhibitor, and the combination of yohimbine and L-arginine (NitroMed, Boston, MA) are in early phase III development. Early clinical and preclinical studies are investigating new phosphodiesterase inhibitors, cyclic AMP activators, alpha-adrenergic antagonists, dopamine agonists, melanocyte-stimulating hormone, potassium channel modulators, endothelin antagonists, and new nitric oxide donors. The future is bright for this infant field of sexual pharmacotherapy.

Publication types

  • Review

MeSH terms

  • 3',5'-Cyclic-GMP Phosphodiesterases / antagonists & inhibitors
  • Administration, Oral
  • Apomorphine
  • Cardiovascular System / drug effects
  • Contraindications
  • Coronary Disease / physiopathology
  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • Dopamine Agonists / therapeutic use
  • Erectile Dysfunction / complications
  • Erectile Dysfunction / drug therapy*
  • Erectile Dysfunction / surgery
  • Heart / drug effects
  • Humans
  • Male
  • Phosphodiesterase Inhibitors / therapeutic use*
  • Piperazines / pharmacokinetics
  • Piperazines / pharmacology
  • Piperazines / therapeutic use*
  • Prostatectomy
  • Purines
  • Sildenafil Citrate
  • Spinal Cord Injuries / complications
  • Sulfones

Substances

  • Dopamine Agonists
  • Phosphodiesterase Inhibitors
  • Piperazines
  • Purines
  • Sulfones
  • Sildenafil Citrate
  • 3',5'-Cyclic-GMP Phosphodiesterases
  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • PDE5A protein, human
  • Apomorphine